A US company is close to receiving the approval for a new scanning and dye procedure, which could revolutionise the diagnosis and treatment of Alzheimer’s. Philadelphia-based Avid Radiopharmaceuticals has been working for the past few years on a new dye designed to highlight in a PET scan the tell-tale plaque deposits associated with Alzheimer’s disease.